Norisoboldine, a natural AhR agonist, promotes regulatory T cell (Treg) differentiation and disease remission in DSS colitis by repressing glycolysis and decreasing the levels of hexokinase II and glucose transporter 121. This evidence concerns the gene AHR and colitis.